Navigation Links
Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
Date:5/23/2011

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX), an emerging specialty pharmaceutical company, today announced that clinical data highlighting the safety profile of EXPAREL™ (bupivacaine extended-release liposome injection) will be presented at the 2011 International Anesthesia Research Society (IARS) Annual Meeting in Vancouver, British Columbia.

Comprehensive, program-wide safety data for EXPAREL will be presented by Dr. Eugene R. Viscusi, Director, Acute Pain Management, Department of Anesthesiology, Jefferson Medical College, Thomas Jefferson University, on Monday, May 23, 2011 at 2:45 p.m. ET. Dr. Viscusi's presentation, titled "The Safety of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" examines the safety profile of EXPAREL in 823 patients across ten wound infiltration studies and five surgical procedures, including hemorrhoidectomy, bunionectomy, total knee arthroplasty, breast augmentation and hernia repair.

Pacira also announced that comprehensive, program-wide efficacy data for EXPAREL was highlighted at IARS. Dr. Sergio Bergese, associate professor of anesthesiology and neurological surgery, The Ohio State University, presented the poster, titled, "The Efficacy of EXPAREL™, A Multivesicular Liposomal Extended-Release Bupivacaine" on Sunday, May 22, 2011 at 8 a.m. ET. The poster was previously presented May 11, 2011 at the Society for Ambulatory Anesthesia (SAMBA) 26th Annual Meeting in San Antonio; this is the first time that the program wide efficacy and safety data have been presented together.

"We are excited to present these data, which support the utility of EXPAREL across multiple surgical models," said David Stack, president and chief executive officer of Pacira Pharmaceuticals. "While EXPAREL was well-tolerated across all doses, based upon clinical experience
'/>"/>

SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
2. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Hernia Repair Presented at the Postgraduate Assembly in Anesthesiology (PGA)
3. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
4. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
5. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
6. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
8. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
9. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
10. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
11. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Mich. , Oct. 31, 2014  Lycera ... modulators to treat autoimmune disease and cancer, today ... novel synthetic RORgamma agonist product candidates will be ... for Immunotherapy of Cancer (SITC) being held November ... Convention Center, National Harbor, MD.  The poster, entitled ...
(Date:10/31/2014)... -- British Journal of Urology International ... "male orgasmic dysfunction" with their doctor prior to any ... while preserving sexual function     ... paper in the British Journal of Urology International which ... with their doctors the likely impact of treatment options ...
(Date:10/31/2014)... DUBLIN , October 30, 2014 ... ) has announced the addition of the  "Process ...  conference to their offering.      (Logo: ... , Science and Risk Based Approach to Process ... Quality Risk Management FDA Process Validation ...
Breaking Medicine Technology:Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting 2Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... 29, 2010 Reportlinker.com announces that a new ... 2010-2015 In-depth Research Report on ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report SummaryBased on ... Bureau, General Administration of Custom, Ministry of Commerce ...
... Reportlinker.com announces that a new market research report ... The Outlook for Pharmaceuticals to 2012 ... Pharmaceuticals to 2012 is a new collection of management ... individual and highly-detailed analysis of each market, looking at ...
Cached Medicine Technology:Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 2Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 3Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 4Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012 5
(Date:10/31/2014)... (PRWEB) October 31, 2014 Fundraising support for ... greater gains than losses. At noon on Monday, November 10 ... Hospital (SSMH), greater than 20 Susquehanna Health (SH) employees ... to raise awareness and funds for the new Cancer Center ... participants’ heads for this act of love and support to ...
(Date:10/31/2014)... for Healthy Neighborhoods (PRCHN) at Case Western Reserve ... in nearly $13.32 million in federal grants awarded ... The Centers for Disease Control and Prevention (CDC) ... five years. The funds will support the center,s ... environmental, and policy interventions that prevent and reduce ...
(Date:10/31/2014)... Monica Williams-Murphy MD , advanced care planning ... chaos that can occur for people who have not ... Americans who come into the emergency department facing the ... the moment and so are their families." She adds, ... catalyst for a family to get the critical conversations ...
(Date:10/31/2014)... 31, 2014 Activz Whole-Food Nutrition ... Silver line offering natural silver healing support† in ... a century, silver has been used to support natural ... products is the most advanced version available. This latest ... chemical structure that supports the existing healing mechanisms in ...
(Date:10/31/2014)... increases the risk of certain types of breast cancer ... studies show. One study of more than 3,200 ... risk for estrogen receptor-negative and progesterone receptor-positive breast tumors ... long time for white women, but now we are ... John, a senior research scientist at the Cancer Prevention ...
Breaking Medicine News(10 mins):Health News:Susquehanna Health Soldiers + Sailors Memorial Hospital Razing Heads to Fight Cancer 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 2Health News:Case Western Reserve, Cuyahoga County, YMCA of greater Cleveland: Public health grants 3Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Study Confirms Obesity-Breast Cancer Link for Blacks, Hispanics 2
... exercised during pregnancy needed less pain meds, study found ... during pregnancy reduces the amount of pain-killing medication requested ... that included 71 expectant mothers. , Half the ... week of aquarobics during their pregnancy, while the other ...
... the Dallas office of WHR Architects. Ms. Moran, nationally recognized ... Education, Science and Technology practice and broaden the talent base ... , "Anita,s experience and skills complement ... college and university clients," said Mark W. Vaughan AIA, ACHA, ...
... SPRINGFIELD, Mass., Nov. 21 Massachusetts Mutual Life,Insurance ... two,Co-Chief Operating Officers. , ... Officer, Executive Vice President,and Chief Investment Officer, will ... H. Reese, who remains Chairman and Chief Executive,Officer. ...
... NXTM ), a leading manufacturer of innovative ... 2008 Technology Fast 500, a,ranking of the 500 fastest ... America. Rankings are based on percentage of,fiscal year revenue ... more than 20,000 percent during this period. , ...
... by HIV/AIDS in New Jersey and Africa - , ... than 800 local Roche employees are participating in the ... support children infected and affected by HIV/AIDS in New Jersey and ... through the township of Nutley, collect donations for their efforts, and ...
... to take, has fewer side effects than chemotherapy, ... The cancer-fighting pill Iressa works as well as chemotherapy ... , Although neither therapy prolongs survival beyond eight months, ... be a better choice for patients who did not ...
Cached Medicine News:Health News:Aquarobics May Help Ease Labor 2Health News:Anita Moran AIA Joins WHR Dallas 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 2Health News:NxStage(R) Ranked 14th Fastest Growing Company in North America on Deloitte's 2008 Technology Fast 500 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 2Health News:Roche Holds Sixth Annual Children's Walk in Nutley 3Health News:Roche Holds Sixth Annual Children's Walk in Nutley 4Health News:Iressa as Good as Chemotherapy for Lung Cancer 2Health News:Iressa as Good as Chemotherapy for Lung Cancer 3
Toxoplasma IgM II ELISA....
HSV 1 & HSV 2 DFA Test....
Herpes Simplex Virus 2 IgG ELISA....
Herpes Simplex Virus 1 IgG ELISA....
Medicine Products: